Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine

25.01.2005


A group of studies published in the January 24 issue of Archives of Internal Medicine add to the growing body of medical literature about the cardiovascular risks that may be associated with the class of pain-relieving drugs known as COX-2 inhibitors. Archives of Internal Medicine is one of the JAMA/Archives journals.



The Celecoxib Rofecoxib Efficacy and Safety in Comorbodities Evaluation Trial (CRESCENT) evaluated the effects of the COX-2 inhibitors and naproxen on 24-hour blood pressure readings in patients with type 2 diabetes, hypertension, and osteoarthritis. Patients were randomly assigned to receive 200 mg of celecoxib (Celebrex; Pfizer Inc., New York) [n= 136], or 25 mg of rofecoxib once daily (Vioxx, Merck & Co., West Point, Penn.) [n = 138], or 500 mg of naproxen twice daily (Naprosyn; Roche Pharmaceuticals, Basel, Switzerland) [n = 130] for 12 weeks. A total of 65 centers from 7 countries participated in this trial from May 2001 to April 2002. Patient evaluations were conducted at the start of the study and 1, 2, 6, and 12 weeks after randomization.

"Reductions in osteoarthritis symptoms, including pain, mobility, and stiffness, were similar in all treatment groups," the researchers found. "The mean (average) 24-hour systolic [top number in blood pressure reading] blood pressure following 6-weeks of therapy was increased significantly by refecoxib but not by celecoxib or naproxen."


"…these results suggest the need for careful monitoring and control of blood pressure when NSAIDS (non-steroidal anti-inflammatory drugs) or COX-2 inhibitors are chosen for osteoarthritis management for patients with hypertension and type 2 diabetes and further suggest need for careful evaluation of currently available as well as future COX-2-specific inhibitors and nonspecific NSAIDs in this population," the authors conclude.

Observational Study of Patients on COX-2 Inhibitors Does Not Show Increased Cardiovascular Risk

An observational study of 6,250 patients enrolled in the Maryland Medicaid program found that COX-2 inhibitors did not increase the risk for cardiovascular events over nonnaproxen NSAIDs in a high-risk population.

Fadia T. Shaya, Ph.D., M.P.H., from University of Maryland, Baltimore, and colleagues analyzed the claims of noninstituionalized Medicaid enrollees who received at least a 60-day supply of a COX-2 inhibitor or other prescription NSAID between June 2000 and June 2002. Naproxen users were excluded. Of the 6,250 patients, 1,005 used a COX-2 inhibitor and 5,245 used some other NSAID. The patients in the study were 70 percent female, 50 percent African American, and 30 percent were older than 50 years. "Overall, 12 percent of the patients had at least one cardiovascular thrombotic [blood clotting] event after treatment within the follow-up period," the researchers report.

The authors conclude: "The results of this analysis do not show a difference in the rate of cardiovascular events between COX-2 inhibitors and nonnaproxen NSAIDs. Given that the study population had higher baseline cardiovascular risk, these observations provide more confidence that the widespread use of COX-2 inhibitors will not be associated with an increase in thrombotic or coronary artery events. This is particularly important because NSAIDs are often used in older, higher-risk patients."

Patients Taking Warfarin Along With NSAIDs or COX-2 Inhibitors Have Increased Risk of Upper Gastrointentinal Hemorrhage

Patients taking warfarin at the same time as selective COX-2 inhibitors or nonselective NSAIDs have an increased risk of hospitalization for upper gastrointestinal (GI) hemorrhage, according to Canadian researchers analyzing health care databases. Warfarin is an anti-coagulant (blood thinner used to prevent clots) commonly used in patients with a variety of thromboembolic [blood vessel blocking, usually by a clot] condition.

Marisa Battistella, B.Sc.Phm., Pharm.D., from University Health Network-Toronto General Hospital, Toronto, and colleagues analyzed information from multiple linked health care databases over one year from April 1, 2000 to March 31, 2001 to identify a group of patients who were older than 66 years of age and continuously prescribed warfarin.

"During the study period, we identified 98,821 elderly patients continuously receiving warfarin," the researchers report. "Of those 361 (0.3 percent) were admitted to the hospital with upper GI hemorrhage. After adjusting for other potential confounders, case patients were significantly more likely to be also taking nonselective NSAIDs, celecoxib, or rofecoxib prior to hospitalization relative to controls" (patients taking warfarin, but not taking NSAIDs or COX-2 inhibitors).

"Our findings suggest that the risk of upper GI hemorrhage is similarly heighted in warfarin users treated with either selective COX-2 inhibitors or nonselective NSAIDs. … physicians and pharmacists who care for elderly patients taking warfarin should be aware of the potential risks of concomitant therapy with NSAIDs or COX-2 inhibitors, particularly because the latter are among the fastest-growing class of prescription medications and have rapidly gained acceptance in clinical practice." (Arch Intern Med. 2005; 165:189-192. Available post-embargo at www.archinternmed.com) Editor’s Note: Please see study for financial disclosures.

Editorial: Coxibs, Science, and the Public Trust

In an editorial accompanying all of the studies, Daniel H. Solomon, M.D., M.P.H., from Brigham and Women’s Hospital, Boston, and Jerry Avorn, M.D., of Harvard University School of Medicine, write that the withdrawal of rofecoxib (Vioxx) from the market in September 2004 by its manufacturer, Merck & Co., "raises many questions concerning drug policy, scientific evidence, and treatment alternatives. Several of these questions are raised by articles in this issue of the ARCHIVES."

"Several lessons can be learned from the 5-year experience and eventual withdrawal of rofecoxib from the market. First, the current postmarketing surveillance system does not work. If the FDA is to continue to approve drugs rapidly, we should not expect that all safety issues will be understood prior to a drug’s approval." The editorial authors add that an improved system of postmarketing surveillance is needed.

"Fortunately, many patients taking coxibs can be switched to other equally effective and evidence-based analgesic (pain relieving) regimens."

"The market withdrawal of rofecoxib has brought to the forefront concerns about the drug safety system that have been raised before. These issues must be addressed now if we are to restore the public’s confidence in the safety of our pharmacologic armamentarium and provide physicians and patients with the data we all need to prescribe drugs safely."

Jane Shaskan | EurekAlert!
Further information:
http://www.jama.com
http://www.archinternmed.com

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>